These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

771 related articles for article (PubMed ID: 23999048)

  • 1. Serum free light chains in clinical laboratory diagnostics.
    Jenner E
    Clin Chim Acta; 2014 Jan; 427():15-20. PubMed ID: 23999048
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessing the efficiency of free light chain assay in monitoring patients with multiple myeloma before and after autologous stem cell transplantation along with serum protein electrophoresis and serum protein immunofixation.
    Dogaru M; Lazăr V; Coriu D
    Roum Arch Microbiol Immunol; 2011; 70(1):15-22. PubMed ID: 21717807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of the analytical performance and the sensitivity of serum free light chains immunoassay in patients with monoclonal gammopathy.
    Wolff F; Thiry C; Willems D
    Clin Biochem; 2007 Mar; 40(5-6):351-4. PubMed ID: 17239359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elimination of the need for urine studies in the screening algorithm for monoclonal gammopathies by using serum immunofixation and free light chain assays.
    Katzmann JA; Dispenzieri A; Kyle RA; Snyder MR; Plevak MF; Larson DR; Abraham RS; Lust JA; Melton LJ; Rajkumar SV
    Mayo Clin Proc; 2006 Dec; 81(12):1575-8. PubMed ID: 17165636
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Replacing urine protein electrophoresis with serum free light chain analysis as a first-line test for detecting plasma cell disorders offers increased diagnostic accuracy and potential health benefit to patients.
    McTaggart MP; Lindsay J; Kearney EM
    Am J Clin Pathol; 2013 Dec; 140(6):890-7. PubMed ID: 24225758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum free light chain assay reduces the need for serum and urine immunofixation electrophoresis in the evaluation of monoclonal gammopathy.
    Fulton RB; Fernando SL
    Ann Clin Biochem; 2009 Sep; 46(Pt 5):407-12. PubMed ID: 19641008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Detection of serum free light chain and its clinical significance in nonsecretory multiple myeloma].
    Chen HF; Hou J; Yuan ZG; Wang DX; Fu WJ; Chen YB
    Zhonghua Xue Ye Xue Za Zhi; 2008 Feb; 29(2):113-6. PubMed ID: 18681313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic performance of quantitative kappa and lambda free light chain assays in clinical practice.
    Katzmann JA; Abraham RS; Dispenzieri A; Lust JA; Kyle RA
    Clin Chem; 2005 May; 51(5):878-81. PubMed ID: 15774572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The serum heavy/light chain immunoassay: A valuable tool for sensitive paraprotein assessment, risk, and disease monitoring in monoclonal gammopathies.
    Greil C; Ihorst G; Gaiser F; Salzer U; Bisse E; Kastritis E; Ludwig H; Wäsch R; Engelhardt M
    Eur J Haematol; 2017 Nov; 99(5):449-458. PubMed ID: 28886228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Can serum free light chains replace urine electrophoresis in the detection of monoclonal gammopathies?
    Beetham R; Wassell J; Wallage MJ; Whiteway AJ; James JA
    Ann Clin Biochem; 2007 Nov; 44(Pt 6):516-22. PubMed ID: 17961305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The evolving use of serum free light chain assays in haematology.
    Pratt G
    Br J Haematol; 2008 May; 141(4):413-22. PubMed ID: 18318757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical usefulness of serum free light chain measurement in monoclonal gammopathy].
    Shimazaki C; Murakami H; Sawamura M; Matsuda M; Kinoshita T; Hata H; Sugiura I; Tsushita K; Nagura E; Kosugi H; Itoh J; Shimizu K
    Rinsho Ketsueki; 2010 Apr; 51(4):245-52. PubMed ID: 20467220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Usefulness of a free light chain immunoassay in serum for the diagnosis and the follow-up of monoclonal gammopathy].
    Guenet L; Decaux O; Lechartier H; Ropert M; Grosbois B
    Rev Med Interne; 2007 Oct; 28(10):689-97. PubMed ID: 17566612
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical usefulness of free light chain concentration as a tumor marker in multiple myeloma.
    Kang SY; Suh JT; Lee HJ; Yoon HJ; Lee WI
    Ann Hematol; 2005 Sep; 84(9):588-93. PubMed ID: 15883850
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic performance of serum free light chain measurement in patients suspected of a monoclonal B-cell disorder.
    Vermeersch P; Van Hoovels L; Delforge M; Mariën G; Bossuyt X
    Br J Haematol; 2008 Nov; 143(4):496-502. PubMed ID: 18729849
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum free light chain measurement aids the diagnosis of myeloma in patients with severe renal failure.
    Hutchison CA; Plant T; Drayson M; Cockwell P; Kountouri M; Basnayake K; Harding S; Bradwell AR; Mead G
    BMC Nephrol; 2008 Sep; 9():11. PubMed ID: 18808676
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Determination of light chains in serum].
    Hansen CT; Nielsen L; Münster AM; Abildgaard N
    Ugeskr Laeger; 2010 Aug; 172(34):2302-5. PubMed ID: 20727297
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of serum immunofixation electrophoresis and free light chain assays in the detection of monoclonal gammopathies.
    Wood PB; McElroy YG; Stone MJ
    Clin Lymphoma Myeloma Leuk; 2010 Aug; 10(4):278-80. PubMed ID: 20709664
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitation of serum free light chains does not compensate for serum immunofixation only when screening for monoclonal gammopathies.
    Böer K; Deufel T
    Clin Chem Lab Med; 2009; 47(9):1109-15. PubMed ID: 19728853
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 39.